MarketCap
Regeneron Pharmaceuticals REGN
$ 916.16
-0.5%
Facebook
X
Telegram
Regeneron Pharmaceuticals Operating Cycle | REGN
Annual Operating Cycle Regeneron Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 | 153 | 153 | 170 | 104 | 112 | 785 | 1.09 K | 790 | 607 | 352 | 361 | 320 | 307 | 1.26 K | 2.06 | 1.38 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 K | 1.38 | 395 |
Quarterly Operating Cycle Regeneron Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 144 | - | 139 | 176 | 145 | 141 | 157 | 145 | 148 | 151 | - | 86.2 | 77.3 | 167 | - | 165 | 99.2 | 150 | 155 | 164 | 192 | 155 | 103 | 110 | 121 | 127 | 81.6 | 94.5 | 97.8 | 98.5 | 88.7 | 93.6 | 95.5 | 99.7 | 99.9 | 100 | 101 | 94.8 | 95.8 | 92.5 | 105 | 99.3 | 84.1 | 93 | 101 | 111 | 118 | 120 | 157 | 143 | 131 | 127 | 178 | 122 | 21 | 25.1 | 23.9 | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 192 | 21 | 117 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Bio-Techne Corporation
TECH
|
233 | $ 72.83 | -0.01 % | $ 11.4 B |  USA |
 |
Sage Therapeutics
SAGE
|
408 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
405 | - | - | $ 1.62 B |  Israel |
 |
Forma Therapeutics Holdings
FMTX
|
5.57 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
358 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
144 | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
585 | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
337 | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
71.3 | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
160 | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
GeoVax Labs
GOVX
|
48.4 | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
198 | $ 588.33 | 1.01 % | $ 26.1 B | USA |
 |
Seelos Therapeutics
SEEL
|
63.2 | - | -47.76 % | $ 6.27 M | USA |
 |
Vericel Corporation
VCEL
|
187 | $ 59.02 | 1.08 % | $ 2.97 B | USA |
 |
Veracyte
VCYT
|
57.4 | $ 24.05 | -7.21 % | $ 1.89 B | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
GlaxoSmithKline plc
GSK
|
0.04 | $ 51.25 | -0.56 % | $ 208 B |  Britain |
 |
Vanda Pharmaceuticals
VNDA
|
136 | $ 4.07 | -0.49 % | $ 240 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
27.2 | $ 3.55 | -1.11 % | $ 37.8 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
375 | $ 547.74 | -0.57 % | $ 140 B | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Wave Life Sciences Ltd.
WVE
|
11.5 | $ 3.41 | -2.01 % | $ 575 M |  Singapore |
 |
Molecular Templates
MTEM
|
4.53 | - | -23.43 % | $ 495 K | USA |
 |
Exicure
XCUR
|
-4.16 | $ 1.08 | 21.31 % | $ 6.8 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
558 | $ 15.81 | -0.35 % | $ 2.54 B | USA |
 |
Insmed Incorporated
INSM
|
400 | $ 119.55 | 2.97 % | $ 23.8 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
259 | $ 28.02 | -9.63 % | $ 4.48 B | USA |
 |
BioXcel Therapeutics
BTAI
|
1.66 K | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
214 | $ 1.78 | 16.33 % | $ 1.2 B | Israel |
 |
22nd Century Group
XXII
|
169 | $ 1.46 | -10.43 % | $ 269 K | USA |